ARTICLE | Company News

MorphoSys, Novartis deal

September 29, 2008 7:00 AM UTC

MorphoSys exercised its first option to participate in development of an antibody under its 2007 deal with Novartis. The antibody's target and intended indication are undisclosed. Novartis will fund development until the antibody reaches preclinical development. Afterward, MorphoSys may opt for a formal co-development agreement, under which it would share costs and profits with Novartis. ...